Sven Stegemann, Leibniz JointLab “First in Translation
Sven Stegemann
Chief Executive Officer
Leibniz JointLab “First in Translation

Sven Stegemann is the Chief Executive Officer of the Leibniz JointLab “First in Translation” (fiT) in Aachen (Germany) and since 2014 professor of patient centric drug design and manufacturing at the Graz University of Technology (Austria). He is pharmacist with a PhD in Pharmacology and worked for 30-years in the pharmaceutical industry, as an advisor to the global pharmaceutical industry on ways to improve the formulation design, development and manufacturing, controls as well as portefolio management, licensing and business development. Since 2022 he is the CEO of the Leibniz JointLab fiT a newly build clinical manufacturing facility embedded in the RWTH & University Hospital Aachen campus translating academic research into clinical evidence. In his academic role, he focuses his research on patient centric drug product design, advanced manufacturing technologies, translational research of innovative cell- and gene therapies as well as education and training of students and young scientists.